CaRi-heart technology
Revolutionary new technology to assess the risk of a serious heart condition or heart attack – many years before anything happens.
Professor Charles Swanton
Consultant Oncologist & Clinician Scientist
Professor Charles Swanton FRCP BSc PhD is a clinician scientist focusing his work on understanding the challenges inherent in the management of metastatic cancer and their drug resistant and incurable nature. He completed his PhD in 1998 at the Imperial Cancer Research Fund through the UCL MBPhD programme, followed by medical oncology and CRUK-funded postdoctoral clinician scientist training in 2008.
In 2008, he was appointed CRUK Senior Clinical Research Fellow, Group Leader of the Translational Cancer Therapeutics laboratory, and Consultant Medical Oncologist at the Royal Marsden Hospital.
In 2011, he became Chair in Personalised Cancer Medicine at the UCL Cancer Institute and Consultant Thoracic Medical Oncologist at UCL Hospitals.
Professor Swanton is Chief Investigator of the CRUK TRACERx study on lung cancer evolution and co-director of the CRUK Lung Cancer Centre of Excellence. He has published over 200 papers in leading journals, advancing understanding of intratumour heterogeneity and cancer evolution, and identifying mechanisms driving cancer diversity and drug resistance.
He is a Fellow of the Royal College of Physicians, Fellow of the Academy of Medical Sciences, Fellow of the Royal Society, and Fellow of the American Association for Cancer Research. He has received numerous major international awards recognising his contributions to cancer research.
Professor Swanton is a co chief investigator of the NHS Galleri trial and a global authority on multi cancer early detection (MCED).
In his session, he will share the latest progress in MCED testing and discuss its potential to transform earlier diagnosis and improve patient outcomes.
The future of early cancer detection screening technologies
Key takeaways
- MCED remains a promising tool for early cancer detection.
- Despite Galleri not meeting it's primary end point, the trial showed encouraging data, and technology continues to evolve.
- As MCED technology evolves it will shape the future of early cancer detection. HCA UK is well positioned to mobilise when it reaches clinical readiness.